Authors Disease Cell type Route of administration Results, any serious adverse events (SAE) Koc et al [48]. Hurlers syndrome, metachromatic leukodystrophy Allogenic BMT following BMT Intravenous No clinical improvement, NO SAE Kondziolka et al. [49] Basal ganglia CVA Human neural cells generated from human neural progenitors Stereotactic surgery Improvement in 6 patients, no SAE Kondziolka et al. [49] Basal ganglia CVA Human neural cells generated from human neural progenitors Stereotactic surgery Safe and feasible, improvement in some patients, AE: syncope, subdural hematoma, seizures Savitz et al [50]. Basal ganglia CVA Porcine cells treated with anti MHC1 antibody CT guided stereotactic transplantation Two patients showed in speech and language, FDA termination. AE: seizures, worsening of motor deficits Bang et al. [51] MCA CVA Autologous MSC Intravenous Some clinical improvement. No SAE Olanow et al [52]. PD Fetal niagral cells Stereotactic implantation Some improvement. AE: dyskinesias Mendez et al [53]. PD Fetal mesencephalic cells Stereotactic implantation Some improvement. No AE Reuter et al [54]. HD Fetal striatal allografts Stereotactic implantation Improvement in motor function. PET showed cell differentiationand integration of transplanted tissue. No AE. Lee et al [55]. MSA Autologous BM, MSC Intra arterial and repeated intravenous Significant clinical and radiological improvement. No AE Deda et al [56]. ALS Autologous BM HSCT Cervical spinal cord implantation Safety indications of clinical satblisation. Improvement confirmed by EMG in some patients. AE: 3 patients died from lung infection and mI Karussis et al [57]. MS Autologous BM MSC Intrathecal and intravenous Safe and feasible. Some indications of disease stabilization. No AE Karussis et al [57]. MS Autologous BM MSC Intrathecal and intravenous Safe and feasible. Indiaction of clinical benefits by in vivo imuunomodulatory effects. No AE Connick et al [58]. MS Autologous BM MSC intravenous Safe and feasible. Neuroprotection evidence by end points parameters. No AE Burt et al [59]. MS Intense immunosupression followed by autologous HSCT intravenous No effective in patients with progressive MS and high disability scores. AE: 2 patients died. Saccardi et al [60]. MS Autologous HSCT intravenous Prolonged clinical stabilization in severe progressive MS resulting in sustained treatment free periods and quality of life improvement. No SAE. Infections only to three month period post transplantation Sampaolesi et al [61]. MS Autologous HSCT intravenous Some clinical benefits in PMS. AE: 2 patients died of severe pneumonia and VZV. Burt et al [62]. MS Non myeloablative autologous BM HSCT intravenous Safe and clinical improvement seen. No AE Krasulova et al [63] MS Autologous HSCT intravenous Clinical improvement. No AE Mancardi et al [64]. MS Autologous BM HSCT intravenous Suppression of disease progression in RRMS. No AE. MS: Multiple Sclerosis, PD: Parkinsons disease; ALS: amyotrophic lateral sclerosis, MSA: multiple system atrophy; HD: Huntingtons Disease, CVA: cerebrovascular accident; MCA: middle cerebral artery

Table 2: A partial list of clinical studies of cell transplantation other than India [47].